VA
IRWD icon

Vident Advisory’s Ironwood Pharmaceuticals IRWD Stock Holding History

Vident Advisory’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$762K Sell
180,929
-3,408
-2% -$13.1K 0.01% 1131
2026
Q1 		$647K Buy
+184,337
New +$756K 0.01% 1114
2024
Q1 		– Sell
-19,619
Closed -$224K – 1366
2023
Q4 		$224K Buy
19,619
+3,743
+24% +$37K 0.01% 1160
2023
Q3 		$153K Buy
+15,876
New +$156K ﹤0.01% 1161

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vident Advisory's IRWD Position: Q2 2026 in Review

Vident Advisory reduced its Ironwood Pharmaceuticals (IRWD) stake by 1.8% in Q2 2026, selling an estimated $13.1K and leaving 180,929 shares worth $762K. The position accounts for 0.01% of the portfolio, ranked #1131.

Vident Advisory first reported a position in IRWD in Q3 2023 and has held it in 4 quarters since. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Vident Advisory held 180,929 shares of Ironwood Pharmaceuticals worth $762K as of Q2 2026.
  • Vident Advisory sold 3,408 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $13.1K.
  • Ironwood Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1131 holding.
  • Vident Advisory first reported a position in Ironwood Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.